デフォルト表紙
市場調査レポート
商品コード
960898

坐骨神経痛:2030年までの市場分析、疫学、市場予測

Sciatica - Market Insights, Epidemiology and Market Forecast-2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 188 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.50円
坐骨神経痛:2030年までの市場分析、疫学、市場予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 188 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

坐骨神経痛は、坐骨神経の刺激に起因する下肢の痛みであり、通常、腰(腰部)から太ももの後ろまで感じられ、膝の下に広がることがあります。坐骨神経は体の中で最大の神経であり、腰の腰部脊髄の神経根から始まって臀部領域を通り、末端が下肢まで伸びています。坐骨神経痛という用語は、L1からL4までの神経根の痛みと刺激に限定されますが、関連領域も含まれる場合があります。

坐骨神経痛は主に高齢者に発症します。患者は一般的にプライマリケアで治療されますが、手術が行われることもあります。坐骨神経痛の多くは、神経根圧迫を伴う椎間板ヘルニアによって引き起こされますが、腰部狭窄と腫瘍が原因となる場合もあります。

当レポートは、米国、ドイツ、フランス、イタリア、スペイン、英国、日本の主要7ヶ国の2030年までの坐骨神経痛の疫学について展望したもので、SWOT分析、疾病の背景と概要、治療法、疫学と患者数、国別の疫学、現在の治療法、未対応のニーズ、新たな治療薬、市場の成長促進要因と阻害要因などの情報を提供しています。

目次

第1章 主な調査結果

第2章 エグゼクティブサマリー

第3章 SWOT分析

第4章 市場の概要

第5章 疾患の背景と概要

  • イントロダクション
  • 坐骨神経痛と腰痛の違い
  • 坐骨神経痛の症状
  • 坐骨神経痛の原因
    • 脊椎椎間板ヘルニア
    • 脊椎狭窄
    • 妊娠
    • 梨状筋症候群
    • 変形性関節症
    • 脊椎症と脊椎すべり症
    • 椎間板以外の原因
  • 椎間板関連の坐骨神経痛の病態生理
    • 臨床観察
    • 坐骨神経痛の生理的変異
  • 根性痛の病態生理学的機序
    • 炎症性機序
    • 免疫学的機序
    • 圧迫性機序
    • 腰部脊椎管狭窄症
    • 神経根障害の骨格的原因
    • 腰椎の隆起または椎間板ヘルニア
  • 予後
  • 坐骨神経痛のバイオマーカー
  • 坐骨神経痛の診断
    • 坐骨神経痛の指標
    • 画像診断
    • 選択的神経根ブロック(SRNB)
  • 鑑別診断
  • 診断のための臨床ガイドライン
  • 診断アルゴリズム
  • 予防

第6章 著名な施設

第7章 治療

  • 非外科的治療
    • 理学療法
    • 心理療法
  • 外科的治療

第8章 米国内科学会(ACP)の腰痛治療のためのガイドライン

第9章 英国国立臨床研究所(NICE)の治療のためのガイドライン

第10章 疫学と患者人口

  • 主な調査結果
  • 疫学調査手法
  • 主要7ヶ国の坐骨神経痛の有病者数

第11章 国別の疫学

  • 米国
    • 前提と根拠
    • 坐骨神経痛の有病率
    • 原因別の有病率
    • 性別の有病率
    • 年齢別の有病率
    • 手術適格患者数
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第12章 未対応のニーズ

第13章 新たな医薬品

  • 主な競合企業
  • SP-102(Semdexa):Scilex Holding Company
  • Hernicore(SI-6603 / Condoliase):Seikagaku Corporation
  • Clonidine Micropellets:Sollis Therapeutics
  • SX600:SpineThera
  • KLS-2031:Kolon Life Science
  • KTP-001:Teijin America

第14章 主要7ヶ国の市場分析

  • 主な調査結果

第15章 属性分析

第16章 主な市場の前提条件

  • 主要7ヶ国の市場規模
  • 主要7ヶ国の治療法別の市場規模
  • 主要7ヶ国の市場見通し
  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第17章 症例報告

  • 24歳男性の腰椎神経根症状
  • 腰椎神経根症の理学療法リハビリテーション
  • 骨粗しょう症性脊椎骨折後の孔狭窄から生じる遅発性腰椎神経根症の脊髄内視鏡検査:新しい外科的戦略の症例報告

第18章 市場の成長促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Sciatica, Epidemiology, and Key Events (2017-2030)
  • Table 2: Non-discogenic causes of Sciatica
  • Table 3: Physiologic Variants of Sciatica
  • Table 4: Total Prevalent Population of Sciatica in the 7MM (2017-2030)
  • Table 5: Prevalence of Sciatica in the United States (2017-2030)
  • Table 6: Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 7: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 8: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 9: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 10: Surgery Eligible Patient Pool in the United States (2017-2030)
  • Table 11: Prevalence of Sciatica in Germany (2017-2030)
  • Table 12: Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 13: Cause-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 14: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 15: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 16: Surgery Eligible Patient Pool in Germany (2017-2030)
  • Table 17: Prevalence of Sciatica in France (2017-2030)
  • Table 18: Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 19: Cause-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 20: Gender-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 21: Age-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 22: Surgery Eligible Patient Pool in France (2017-2030)
  • Table 23: Prevalence of Sciatica in Italy (2017-2030)
  • Table 24: Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 25: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 26: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 27: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 28: Surgery Eligible Patient Pool in Italy (2017-2030)
  • Table 29: Prevalence of Sciatica in Spain (2017-2030)
  • Table 30: Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 31: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 32: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 33: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 34: Surgery Eligible Patient Pool in Spain (2017-2030)
  • Table 35: Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 36: Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 37: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 38: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 39: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 40: Surgery Eligible Patient Pool in the United Kingdom (2017-2030)
  • Table 41: Prevalence of Sciatica in Japan (2017-2030)
  • Table 42: Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 43: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 44: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 45: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 46: Surgery Eligible Patient Pool in Japan (2017-2030)
  • Table 47: Comparison of Emerging Drugs
  • Table 48: SP-102, Clinical Trial Description,2020
  • Table 49: Hernicore, Clinical Trial Description, 2020
  • Table 50: Clonidine Micropellets, Clinical Trial Description, 2020
  • Table 51: SX600, Clinical Trial Description, 2020
  • Table 52: KLS-2031, Clinical Trial Description, 2020
  • Table 53: KTP-001, Clinical Trial Description, 2020
  • Table 54: Key Market Assumptions for Hernicore (Condoliase)
  • Table 55: Key Market Assumptions for SP-102
  • Table 56: Seven Major Market Size of Sciatica in USD Million (2017-2028)
  • Table 57: Market size of Sciatica by Therapies in the 7MM, in USD Million (2017-2030)
  • Table 58: United States Market Size of Sciatica, USD Million (2017-2030)
  • Table 59: Market size of Sciatica by Therapies in the United States, in USD Million (2017-2030)
  • Table 60: Market Size of Sciatica in Germany, in USD Million (2017-2030)
  • Table 61: Market size of Sciatica by Therapies in Germany, in USD Million (2017-2030)
  • Table 62: Market Size of Sciatica in France, in USD Million (2017-2030)
  • Table 63: Market size of Sciatica by Therapies in France, in USD Million (2017-2030)
  • Table 64: Market Size of Sciatica in Italy, in USD Million (2017-2030)
  • Table 65: Market size of Sciatica by Therapies in Italy, in USD Million (2017-2030)
  • Table 66: Market Size of Sciatica in Spain, in USD Million (2017-2030)
  • Table 67: Market size of Sciatica by Therapies in Spain, in USD Million (2017-2030)
  • Table 68: Market Size of Sciatica in the UK, in USD Million (2017-2030)
  • Table 69: Market size of Sciatica by Therapies in the UK, in USD Million (2017-2030)
  • Table 70: Market Size of Sciatica in Japan, in USD Million (2017-2030)
  • Table 71: Market size of Sciatica by Therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis of Sciatica
  • Figure 2: The sciatic nerve runs from the back, under the buttock, and downward through the hip area into each leg
  • Figure 3: Types of lumbar disc herniation classification based on the location of the disc herniation relative to the facet joint and spinal canal.
  • Figure 4: Lumbar spinal stenosis is a common cause of Sciatica
  • Figure 5: Piriformis Muscles Syndrome
  • Figure 6: Pathophysiological mechanisms in radicular pain.
  • Figure 7: Pathoanatomical Features of Degenerative Lumbar Spinal Stenosis
  • Figure 8: Algorithm for the diagnostic evaluation of patients with low-back pain.
  • Figure 9: Treatment algorithm of Sciatica
  • Table 10: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Table 11: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Figure 12: Total Prevalent Population of Sciatica in the 7MM (2017-2030)
  • Figure 13: Prevalence of Sciatica in the United States (2017-2030)
  • Figure 14: Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 15: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 16: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 17: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 18: Surgery Eligible Patient Pool in the United States (2017-2030)
  • Figure 19: Prevalence of Sciatica in Germany (2017-2030)
  • Figure 20: Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 21: Cause-specific Diagnosed Prevalence of Sciatica of Sciatica in Germany (2017-2030)
  • Figure 22: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 23: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 24: Surgery Eligible Patient Pool in Germany (2017-2030)
  • Figure 25: Prevalence of Sciatica in France (2017-2030)
  • Figure 26: Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 27: Cause-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 28: Gender-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 29: Age-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 30: Surgery Eligible Patient Pool in France (2017-2030)
  • Figure 31: Prevalence of Sciatica in Italy (2017-2030)
  • Figure 32: Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 33: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 34: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 35: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 36: Surgery Eligible Patient Pool in Italy (2017-2030)
  • Figure 37: Prevalence of Sciatica in Spain (2017-2030)
  • Figure 38: Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 39: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 40: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 41: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 42: Surgery Eligible Patient Pool in Spain (2017-2030)
  • Figure 43: Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 44: Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 45: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 46: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 47: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 48: Surgery Eligible Patient Pool in the United Kingdom (2017-2030)
  • Figure 49: Prevalence of Sciatica in Japan (2017-2030)
  • Figure 50: Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 51: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 52: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 53: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 54: Surgery Eligible Patient Pool in Japan (2017-2030)
  • Figure 55: Unmet Needs of Sciatica
  • Figure 56: Seven Major Market Size of Sciatica in USD Million (2017-2030)
  • Figure 57: Market size of Sciatica by Therapies in the 7MM, in USD Million (2017-2030)
  • Figure 58: Market Size of Sciatica in the United States, USD Millions (2017-2030)
  • Figure 59: Market size of Sciatica by Therapies in the US, in USD Million (2017-2030)
  • Figure 60: Market Size of Sciatica in Germany, USD Million (2017-2030)
  • Figure 61: Market size of Sciatica by therapies in Germany, in USD Million (2017-2030)
  • Figure 62: Market Size of Sciatica in France, USD Million (2017-2030)
  • Figure 63: Market size of Sciatica by therapies in France, in USD Million (2017-2030)
  • Figure 64: Market Size of Sciatica in Italy, USD Million (2017-2030)
  • Figure 65: Market size of Sciatica by therapies in Italy, in USD Million (2017-2030)
  • Figure 66: Market Size of Sciatica in Spain, USD Million (2017-2030)
  • Figure 67: Market Size of Sciatica by therapies in Spain, in USD Million (2017-2030)
  • Figure 68: Market Size of Sciatica in the UK, USD Million (2017-2030)
  • Figure 69: Market Size of Sciatica by therapies in the UK, in USD Million (2017-2030)
  • Figure 70: Market Size of Sciatica in Japan, USD Million (2017-2030)
  • Figure 71: Market size of Sciatica by therapies in Japan, in USD Million (2017-2030)
  • Figure 72: Market Drivers
  • Figure 73: Market Barriers
目次
Product Code: DIMI0572

DelveInsight's 'Sciatica-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Sciatica, historical and forecasted epidemiology as well as the Sciatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sciatica market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Sciatica market size from 2017 to 2030. The report also covers current Sciatica treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Sciatica Disease Understanding and Treatment Algorithm

Sciatica Overview

Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low back and extends through the buttock area to send nerve endings down the lower limb. Radiculopathy is sometimes referred to as sciatic nerve pain. Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is a specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The term sciatica is limited to the pain and irritation in nerve roots from L1 to L4 and may also involve related areas. Many times patients and clinicians use Sciatica to describe any pain arising from the lower back and radiating down to the leg.

Sciatica affects mainly people of older age. The most important indications of pain arousal are radiating leg pain and related disabilities. Patients are commonly treated in primary care, but a small proportion is referred to secondary care, which may eventually end up in surgery. Synonyms for sciatica pain are lumbosacral radicular syndrome, ischias, nerve root pain, and nerve root entrapment. In maximum cases, it is caused by a herniated disc with nerve root compression, but lumbar stenosis and tumors are other possible causes. The diagnosis of Sciatica and its management is different from location to location as the surgery rates for lumbar discectomy vary widely between countries, large variation in disc surgery, even within countries can also be noticed. This may in part, be due to the scarcity of evidence on the value of diagnostic and therapeutic interventions and a lack of clear clinical guidelines reflect differences in healthcare and insurance systems.

Sciatica Diagnosis

Sciatica is mainly diagnosed by history taking and physical examination. By definition, patients mention burning pain in the leg. The patient is asked to report the distribution of the pain and whether it radiates below the knee and to draw or mark the area which may be used to evaluate the distribution. Sciatica is characterized by radiating pain that follows a dermatomal pattern. Patients may also report sensory symptoms.

Physical examination largely depends on neurological testing. The most applied investigation is the straight leg raising test or Lasegue's sign. Patients with Sciatica may also have slight back pain, but this is usually less severe than the leg pain. The diagnostic value of patient history and physical examination has not been well studied. No history examination or physical tests have both high sensitivity and high specificity. The sensitivity of the straight leg raising test is estimated to be very high with a corresponding specificity of being low. A thorough differential list is important in considering a diagnosis of Sciatica and should include- Herniated lumbosacral disc, muscle spasm, nerve root impingement, piriformis syndrome and others.

Sciatica Treatment

Currently, the market of Sciatica holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative treatment of Sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies.

Patients are mostly benefited by physical therapy, which includes multiple options to get relief from the unbearable pain. Several types of deep massages, hot and cold therapies to release muscle tension and pressure thereby enabling the blood flow are preferred.

It covers the details of conventional and current medical therapies available in the Sciatica market for the treatment of the various types of Sciatica. Patients are also advised by the physicians to opt for certain behavioral therapies by which it is easy for them to diagnose and treat the disease efficiently. Talk sessions can help out the patients to exactly know the root cause of their pain. When physical therapy cannot help the patients from the intolerable pain of Sciatica, pharmacological therapies are the next mode of relief advised by the physicians. Several different classes of medications are used for sciatica treatment, such as pain killers, anti-inflammatories, antidepressants, muscle relaxants, calcium channel α2-δ ligands, epidural steroids, topical pain medications, and opioids.

It also provides the treatment guidelines and algorithms of the United States and Europe. DelveInsight's Sciatica market report gives a thorough understanding of Sciatica by including details such as disease definition, causes, pathophysiology, biomarkers, and diagnosis.

Sciatica Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalence of Sciatica, Diagnosed Prevalence of Sciatica, Cause-specific Diagnosed Prevalence of Sciatica, Gender-specific Diagnosed Prevalence of Sciatica, Age-specific Diagnosed Prevalence of Sciatica, Surgery eligible patient pool of Sciatica), scenario of Sciatica in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpses of the Sciatica epidemiology in the 7MM.

  • The total prevalent population of Sciatica in the seven major markets ranges was 27,022,660 in 2017
  • Delveinsight has also analyzed the diagnosed prevalent population of lumbar disc herniation. In 2017, the number of diagnosed prevalent cases of lumbar disc herniation was 7,358,250, which will increase in the forecast period.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States.
  • In 2017, the surgery eligible patient pool in the US was 1,082,736, which is anticipated to increase in the forecast period.
  • The age-specific prevalence of Sciatica was maximum in the age group 45-54 with 2,043,958 cases in 2017 in the US while the lowest number of cases were found in 18-34 age group with 1,218,199 cases in 2017.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States. On the other hand, a similar trend was not observed in EU5, and Japan wherein females are more predominant than males.

Country Wise-Sciatica Epidemiology

The epidemiology segment also provides the Sciatica epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Sciatica Drug Chapters

This segment of the Sciatica report encloses the detailed analysis of the mid- and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Sciatica Emerging Drugs

SP-102 (Semdexa): Semnur Pharmaceuticals/Scilex Holding Company

SP-102 is the first nonopioid corticosteroid formulated as a viscous gel injection, which is under development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. The US Food and Drug Administration (FDA) has granted SP-102 Fast Track Designation for the treatment of lumbar radicular pain/sciatica. SP-102 is currently undergoing crucial Phase III trials with data readout expected in the first half of 2020

Condoliase (Hernicore): Seikagaku Corporation

Hernicore (Condoliase/SI-6603) is developed by Seikagaku Corporation and marketed in Japan which is used as a chemonucleolysis treatment to break down selected components of the IVD, primarily within the nucleus pulposus. This reduces its water content and volume, thereby relieving disc pressure and compression on the spinal nerve root. The treatment for lumbar disc herniation SI-6603, an injectable drug containing condoliase, an enzyme that selectively degrades glycosaminoglycan (GAG) in the herniated nucleus pulposus, and thus when injected directly into the intervertebral disc can reduce pressure on nerves (the source of pain) caused by the herniation, thereby providing relief from the pain. Glycosaminoglycans (GAG) are acidic mucopolysaccharides consisting of a repetitive disaccharide structure of amino sugar and uronic acid or galactose. SI-6603 does not break down proteins, so it does not affect surrounding tissue, such as blood vessels and nerves.

SX600: SpineThera

SX600, a nonopioid epidural steroid injection, a sustained-release, micro-suspension corticosteroid to address the unique requirements to treat back pain. The active ingredient in SX600 is dexamethasone acetate, which has been reformulated into an injectable micro-suspension containing microparticles that are smaller than the particles in a standard corticosteroid suspension and smaller than a red blood cell. The active drug is encapsulated within these tiny, biodegradable microparticles, which provide sustained release delivery of dexamethasone.

Clonidine Micropellets: Sollis Therapeutics

Clonidine is an alpha-2 agonist, an investigational extended-release form of a well-known analgesic and anti-inflammatory medication. The extended-release form is referred to as a "clonidine micropellet" and allows for localized delivery of clonidine to the affected nerves to reduce pain and inflammation via simple, one-time, epidural injection. Moreover, clonidine has been approved for systemic administration by the FDA for several uses because of its potent activity. The first product approved was introduced in 1974 as an orally administered pill for the treatment of hypertension. In 2010, clonidine was also approved for the treatment of attention deficit hyperactivity disorder and was usually administered with a patch.

Products detail in the report…

Sciatica Market Outlook

Patients who have Sciatica are best aided by a treatment plan that is individualized based on the patient's symptoms, diagnosis, and response to various treatments. Many cases of Sciatica go away within a few weeks using conservative treatment methods. However, this is not the case for all patients. For some, Sciatica can last much longer, even for several months.

Currently, the market of Sciatica holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative treatment of Sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies.

Patients are mostly benefited by physical therapy, which includes multiple options to get relief from the unbearable pain. Several types of deep massages, hot and cold therapies to release muscle tension and pressure thereby enabling the blood flow are preferred. It covers the details of conventional and current medical therapies available in the Sciatica market for the treatment of the various types of Sciatica. Patients are also advised by the physicians to opt for certain behavioral therapies by which it is easy for them to diagnose and treat the disease efficiently. Talk sessions can help out the patients to exactly know the root cause of their pain. When physical therapy cannot help the patients from the intolerable pain of Sciatica, pharmacological therapies are the next mode of relief advised by the physicians. Several different classes of medications are used for sciatica treatment, such as pain killers, anti-inflammatories, antidepressants, muscle relaxants, calcium channel α2-δ ligands, epidural steroids, topical pain medications, and opioids. The market of Sciatica exhibit a critical unmet need to improve the quality of life of the patients since there are no FDA approved therapies to treat the indication and the off-label therapies have several side effects.

The Sciatica market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Sciatica market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Sciatica market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Sciatica 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Sciatica 7 MM market.

  • According to Delveinsight estimates, the United States accounts for the largest market size of Sciatica, in comparison to Japan and EU5 (the United Kingdom, Germany, Italy, France, and Spain).
  • The market size of Sciatica in the seven major markets is USD 2,047.28 Million in 2017.
  • Japan accounts for the least market size in 7MM during the forecast period 2017-2030, at a CAGR of 4.24% for the study period (2017-2030)
  • Among the EU5 countries, Germany had the highest market size, with USD 158.45 Million in 2017, while Spain had the smallest market size of Sciatica with USD 91.82 Million.
  • Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Sciatica. Owing to the positive outcomes of the upcoming products during the developmental stage by key players such as Scilex Holdings, Seikagaku Corporation have the potential to create a significant positive shift in the Sciatica Market Size

Sciatica Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017-2030. The analysis covers Sciatica market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sciatica Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Sciatica emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Sciatica market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Sciatica, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Sciatica epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Sciatica is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Sciatica market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Sciatica market.

Report Highlights:

  • Sciatica market is anticipated to increase at a CAGR of 4.57% for the study period 2017-2030.
  • The United States accounted for more than half (59.75%) of the market share in the 7MM.
  • SP-102 is projected to lead the market with the largest market share in 2030.
  • Japan accounts for the second-highest market share (15.79%) in the 7MM.
  • In the coming years, sciatica market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence sciatica R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Sciatica. Launch of emerging therapies will significantly impact the sciatica market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Sciatica Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Sciatica Pipeline Analysis
  • Sciatica Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sciatica Report Key Strengths

  • Eleven Years Forecast
  • 7MMCoverage
  • Sciatica Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Sciatica Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Companies:

  • SP-102 (Semdexa): Scilex Holding Company
  • Hernicore (Condoliase): Seikagaku Corporation
  • Clonidine Micropellets: Sollis Therapeutics
  • SX600: SpineThera
  • KLS-2031: Kolon Life Science
  • KTP-001: Teijin America

Key Questions:

Market Insights:

  • What was the Sciatica market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Sciatica total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Sciatica market size during the forecast period (2020-2030)?
  • At what CAGR, the Sciatica market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Sciatica market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Sciatica market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Sciatica?
  • What is the historical Sciatica patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Sciatica at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to aspergillosis?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Sciatica during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Sciatica along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Sciatica in the US and Europe?
  • What are the Sciatica marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Sciatica?
  • How many therapies are developed by each company for the treatment of Sciatica?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Sciatica?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sciatica therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Sciatica and their status?
  • What are the key designations that have been granted for the emerging therapies for Sciatica?
  • What are the 7MM historical and forecasted market of Sciatica?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Sciatica.
  • To understand the future market competition in the aspergillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Sciatica in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Sciatica market.
  • To understand the future market competition in the Sciatica market.

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Sciatica Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Sciatica in 2017
  • 4.2 Market Share (%) Distribution of Sciatica in 2030

5 Disease Background and Overview: Sciatica

  • 5.1 Introduction
  • 5.2 Difference between Sciatica and Lower Back Pain
  • 5.3 Symptoms of Sciatica
  • 5.4 Causes of Sciatica
    • 5.4.1 Spinal Disc Herniation
    • 5.4.2 Spinal Stenosis
    • 5.4.3 Pregnancy
    • 5.4.4 Piriformis syndrome
    • 5.4.5 Osteoarthritis
    • 5.4.6 Spondylosis and spondylolisthesis
    • 5.4.7 Nondiscogenic causes
  • 5.5 Pathophysiology of disk-related sciatica
    • 5.5.1 Clinical observation
    • 5.5.2 Physiologic Variants of Sciatica
  • 5.6 Pathophysiological Mechanisms in Radicular Pain
    • 5.6.1 Inflammatory mechanism
    • 5.6.2 Immunological mechanism
    • 5.6.3 Compressive mechanism
    • 5.6.4 Lumbar spinal stenosis
    • 5.6.5 Skeletal Causes of Radiculopathy
    • 5.6.6 Lumbar bulging or herniated disc
  • 5.7 Prognosis
  • 5.8 Biomarkers for Sciatica
  • 5.9 Diagnosis of sciatica
    • 5.9.1 Indicators for sciatica
    • 5.9.2 Imaging
    • 5.9.3 Selective Nerve Root Block (SRNB)
  • 5.1 Differential Diagnosis
  • 5.11 Clinical Guidelines for the Diagnosis for Sciatica
    • 5.11.1 Clinical guideline for diagnosis for General Practice
  • 5.12 Diagnostic algorithm
  • 5.13 Prevention of sciatica

6 Recognized Establishments

7 Treatment

  • 7.1 Nonsurgical Treatment for Sciatica
    • 7.1.1 Physical therapy
    • 7.1.2 Psychological therapies
    • 7.1.3 Medications
  • 7.2 Surgical Treatment of Sciatica

8 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain

  • 8.1 Grading the Evidence and Developing Recommendations
  • 8.2 Comparative Benefits of Pharmacologic Therapies
  • 8.3 Comparative Benefits of Nonpharmacologic Therapies
  • 8.4 Recommendations

9 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines

10 Epidemiology and Patient Population

  • 10.1 Key Findings
  • 10.2 Epidemiology Methodology
  • 10.3 7MM Total Prevalent Population of Sciatica

11 Country Wise-Epidemiology of Sciatica

  • 11.1 United States
    • 11.1.1 Assumption and Rationale
    • 11.1.2 Prevalence of Sciatica in the United States
    • 11.1.3 Diagnosed Prevalence of Sciatica in the United States
    • 11.1.4 Cause-specific Diagnosed Prevalence of Sciatica in the United States
    • 11.1.5 Gender-specific Diagnosed Prevalence of Sciatica in the United States
    • 11.1.6 Age-specific Diagnosed Prevalence in the United States
    • 11.1.7 Surgery Eligible Patient Pool in the United States
  • 11.2 EU5 Countries
    • 11.2.1 Assumption and Rationale
  • 11.3 Germany
    • 11.3.1 Prevalence of Sciatica in Germany
    • 11.3.2 Diagnosed Prevalence of Sciatica in Germany
    • 11.3.3 Cause-specific Diagnosed Prevalence of Sciatica in Germany
    • 11.3.4 Gender-specific Diagnosed Prevalence of Sciatica in Germany
    • 11.3.5 Age-specific Diagnosed Prevalence in Germany
    • 11.3.6 Surgery Eligible Patient Pool in Germany
  • 11.4 France
    • 11.4.1 Prevalence of Sciatica in France
    • 11.4.2 Diagnosed Prevalence of Sciatica in France
    • 11.4.3 Cause-specific Diagnosed Prevalence of Sciatica in France
    • 11.4.4 Gender-specific Diagnosed Prevalence of Sciatica in France
    • 11.4.5 Age-specific Diagnosed Prevalence in France
    • 11.4.6 Surgery Eligible Patient Pool in France
  • 11.5 Italy
    • 11.5.1 Prevalence of Sciatica in Italy
    • 11.5.2 Diagnosed Prevalence of Sciatica in Italy
    • 11.5.3 Cause-specific Diagnosed Prevalence of Sciatica in Italy
    • 11.5.4 Gender-specific Diagnosed Prevalence of Sciatica in Italy
    • 11.5.5 Age-specific Diagnosed Prevalence in Italy
    • 11.5.6 Surgery Eligible Patient Pool in Italy
  • 11.6 Spain
    • 11.6.1 Prevalence of Sciatica in Spain
    • 11.6.2 Diagnosed Prevalence of Sciatica in Spain
    • 11.6.3 Cause-specific Diagnosed Prevalence of Sciatica of Sciatica in Spain
    • 11.6.4 Gender-specific Diagnosed Prevalence of Sciatica in Spain
    • 11.6.5 Age-specific Diagnosed Prevalence in Spain
    • 11.6.6 Surgery Eligible Patient Pool in Spain
  • 11.7 United Kingdom
    • 11.7.1 Prevalence of Sciatica in the United Kingdom
    • 11.7.2 Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.3 Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.4 Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.5 Age-specific Diagnosed Prevalence in the United Kingdom
    • 11.7.6 Surgery Eligible Patient Pool in the United Kingdom
  • 11.8 Japan
    • 11.8.1 Assumptions and Rationale
    • 11.8.2 Prevalence of Sciatica in Japan
    • 11.8.3 Diagnosed Prevalence of Sciatica in Japan
    • 11.8.4 Cause-specific Diagnosed Prevalence of Sciatica in Japan
    • 11.8.5 Gender-specific Diagnosed Prevalence of Sciatica in Japan
    • 11.8.6 Age-specific Diagnosed Prevalence in Japan
    • 11.8.7 Surgery Eligible Patient Pool in Japan

12 Unmet Needs

13 Emerging Drugs

  • 13.1 Key Cross Competition
  • 13.2 SP-102 (Semdexa): Scilex Holding Company
    • 13.2.1 Product Description
    • 13.2.2 Other Developmental Activities
    • 13.2.3 Clinical Development
    • 13.2.4 Product Profile
  • 13.3 Hernicore (SI-6603/Condoliase): Seikagaku Corporation
    • 13.3.1 Product Description
    • 13.3.2 Other Developmental Activities
    • 13.3.3 Clinical Development
    • 13.3.4 Product Profile
  • 13.4 Clonidine Micropellets: Sollis Therapeutics
    • 13.4.1 Product Description
    • 13.4.2 Other Developmental Activities
    • 13.4.3 Clinical Development
    • 13.4.4 Product Profile
  • 13.5 SX600: SpineThera
    • 13.5.1 Product Description
    • 13.5.2 Other Developmental Activities
    • 13.5.3 Clinical Development
    • 13.5.4 Product Profile
  • 13.6 KLS-2031: Kolon Life Science
    • 13.6.1 Product Description
    • 13.6.2 Other Developmental Activities
    • 13.6.3 Clinical Development
    • 13.6.4 Product Profile
  • 13.7 KTP-001: Teijin America
    • 13.7.1 Product Description
    • 13.7.2 Other Developmental Activities
    • 13.7.3 Clinical Development
    • 13.7.4 Product Profile

14 Sciatica: Seven Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Methodology

15 Attribute Analysis

16 Key Market Assumptions

  • 16.1 Total Market Size of Sciatica in the 7MM
  • 16.2 Market Size by Therapies in the 7MM
  • 16.3 7MM Market Outlook
  • 16.4 United States Market Size
    • 16.4.1 Total Market size of Sciatica
    • 16.4.2 Market Size by Therapies
  • 16.5 Germany
    • 16.5.1 Total Market size of Sciatica in Germany
    • 16.5.2 Market Size by Therapies
  • 16.6 France
    • 16.6.1 Total Market Size of Sciatica
    • 16.6.2 Market Size by Therapies
  • 16.7 Italy
    • 16.7.1 Total Market Size of Sciatica
    • 16.7.2 Market Size by Therapies
  • 16.8 Spain
    • 16.8.1 Total Market Size of Sciatica
    • 16.8.2 Market Size by Therapies
  • 16.9 United Kingdom
    • 16.9.1 Total Market Size of Sciatica
    • 16.9.2 Market Size by Therapies
  • 16.1 Japan Market Size
    • 16.10.1 Total Market Size of Sciatica
    • 16.10.2 Market Size by Therapies

17 Case Reports

  • 17.1 Lumbar radicular symptoms in a 24-year-old male
  • 17.1 Physical therapy rehabilitation for lumbar radiculopathy: A case report
  • 17.3 Spinal endoscopy for delayed-onset lumbar radiculopathy resulting from foraminal stenosis after osteoporotic vertebral fracture: A case report of a new surgical strategy

18 Market Drivers

19 Market Barriers

20 Appendix

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight